{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T03:00:29Z","timestamp":1772766029734,"version":"3.50.1"},"reference-count":96,"publisher":"Informa UK Limited","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1517\/14656566.2012.712514","type":"journal-article","created":{"date-parts":[[2012,7,31]],"date-time":"2012-07-31T10:37:47Z","timestamp":1343731067000},"page":"1969-1983","source":"Crossref","is-referenced-by-count":9,"title":["Combinational therapies for HIV: a focus on EVG\/COBI\/FTC\/TDF"],"prefix":"10.1517","volume":"13","author":[{"given":"Rik","family":"Schrijvers","sequence":"first","affiliation":[{"name":"Division of Molecular Medicine, Katholieke Universiteit Leuven","place":["Belgium"]},{"name":"University Hospitals Leuven, Department of Internal Medicine","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeger","family":"Debyser","sequence":"additional","affiliation":[{"name":"Division of Molecular Medicine, Katholieke Universiteit Leuven","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2012,7,31]]},"reference":[{"key":"e_1_3_1_3_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.82.20.7096"},{"key":"e_1_3_1_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.624"},{"key":"e_1_3_1_5_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2012.685653"},{"key":"e_1_3_1_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.9.1155"},{"key":"e_1_3_1_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/135965350300800211"},{"key":"e_1_3_1_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031772"},{"key":"e_1_3_1_9_1","unstructured":"Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 1-240. Available from: http:\/\/www.aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf [Accessed 10 May 2012]"},{"issue":"3","key":"e_1_3_1_10_1","first-page":"CD005481","article-title":"A combination drug of abacavir-lamivudine-zidovudine (Trizivir) for treating HIV infection and AIDS","author":"Shey M","year":"2009","unstructured":"Shey M, Kongnyuy EJ, Shang J, Wiysonge CS. A combination drug of abacavir-lamivudine-zidovudine (Trizivir) for treating HIV infection and AIDS. Cochrane Database Syst Rev 2009(3):CD005481","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_1_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32832cbcc2"},{"key":"e_1_3_1_12_1","unstructured":"Pozniak AL Gallant JE DeJesus E Superior outcome for tenofovir DF (RDF) emtricitabine (FTC) and efavirenz (EFV) compared to fixed dose zidovudine\/lamivudine (CBV) and EFV in antiretroviral na\u00efve patients [abstract no. WeOa0202]. The 3rd IAS Conference on HIV Pathogenesis and Treatment; 24 \u2013 27 July 2005; Rio de Janeiro Brazil"},{"key":"e_1_3_1_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051871"},{"issue":"9","key":"e_1_3_1_14_1","first-page":"1112","article-title":"Virological failure and adherence to antiretroviral therapy in HIV-infected patients","volume":"12","author":"Rodriguez-Rosado R","year":"1998","unstructured":"Rodriguez-Rosado R, Jimenez-Nacher I, Soriano V, Virological failure and adherence to antiretroviral therapy in HIV-infected patients. AIDS 1998;12(9):1112-13","journal-title":"AIDS"},{"key":"e_1_3_1_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/00912700122010096"},{"key":"e_1_3_1_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181427835"},{"key":"e_1_3_1_17_1","doi-asserted-by":"publisher","DOI":"10.2147\/ppa.s10330"},{"key":"e_1_3_1_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2008.00618.x"},{"key":"e_1_3_1_19_1","doi-asserted-by":"publisher","DOI":"10.1086\/340312"},{"key":"e_1_3_1_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181a572cf"},{"key":"e_1_3_1_21_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2009.0259"},{"key":"e_1_3_1_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328340a209"},{"key":"e_1_3_1_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031591"},{"key":"e_1_3_1_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1004"},{"key":"e_1_3_1_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0906768"},{"key":"e_1_3_1_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60983-5"},{"key":"e_1_3_1_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60936-7"},{"key":"e_1_3_1_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60992-6"},{"key":"e_1_3_1_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283388742"},{"key":"e_1_3_1_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp334"},{"key":"e_1_3_1_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31824d006e"},{"key":"e_1_3_1_32_1","unstructured":"US Food and Drug Administration. Approval of Edurant (rilpivirine) a new NNRTI for the treatment of HIV in treatment naive patients. 2011.Available from: http:\/\/www.fda.gov\/ForConsumers\/ByAudience\/ForPatientAdvocates\/HIVandAIDSActivities\/ucm256151.htm [Accessed 10 May 2012]"},{"key":"e_1_3_1_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.228"},{"key":"e_1_3_1_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70196-7"},{"key":"e_1_3_1_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000233308.82860.2f"},{"key":"e_1_3_1_36_1","doi-asserted-by":"publisher","DOI":"10.1086\/650698"},{"key":"e_1_3_1_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70249-3"},{"key":"e_1_3_1_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70277-8"},{"key":"e_1_3_1_39_1","unstructured":"German P Mathias A Wei L Cytochrome P450 2D6 2B6 abd O-glycoprotein using phenotypic probes [abstract O_01]. 12th International Workshop on Clinical Pharmacology of HIV Therapy; 13 \u2013 15 April 2011; Miami USA"},{"key":"e_1_3_1_40_1","unstructured":"Ramanathan S Wang H Stondell T Pharmacokinetics and drug interaction profile of cobicistat boosted-elvitegravir with atazanavir rosuvastatin or rifabutin [abstract O_03]. 13th International Workshop on Clinical Pharmacology of HIV Therapy; 16 \u2013 18 April 2012; Barcelona Spain"},{"key":"e_1_3_1_41_1","doi-asserted-by":"publisher","DOI":"10.2165\/11584570-000000000-00000"},{"key":"e_1_3_1_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328345766f"},{"key":"e_1_3_1_43_1","unstructured":"Elion R Gathe J Rashbaum B Single-tablet regimen elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate (EVG\/COBI\/FTC\/TDF; \"QUAD\") maintains a high rate of virologic suppression and cobicistat (COBI) is an effective pharmacoenhancer through 48 weeks [abstract H-938B]. 50th Interscience conference on Antimicrobial Agents and Chemotherapy (ICAAC); 12 \u2013 15 September 2010; Boston USA"},{"key":"e_1_3_1_44_1","unstructured":"Sax P DeJesus E Mills A Elvitegravir\/cobicistat\/emtricitabine\/tenofovir (Quad) has non-inferior efficacy and favorable safety compared to efavirenz\/emtricitabine\/tenofovir in treatment-na\u00efve HIV-1+ subjects [abstract 101]. 19th Conference on Retroviruses and Opportunistic Infections; 5 \u2013 8 March 2012; Seattle USA"},{"key":"e_1_3_1_45_1","unstructured":"Food and Drug Administration\/CDER Web site. Guidance for Industry: Antiretroviral Drugs Using Plasma HIV RNA Measurements - Clinical Considerations for Accelerated and Traditional Approval. 2002. Available from: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM070968.pdf [Accessed 10 May 2012]"},{"key":"e_1_3_1_46_1","unstructured":"DeJesus E Rockstroh J Henry K Week 48 results of an ongoing global phase 3 study comparing elvitegravir\/cobicistat\/emtricitabine\/tenofovir (Quad) with atazanavir\/ritonavir plus emtricitabine\/tenofovir in treatment-naive HIV-1+ subjects showing efficacy safety and pharmacokinetics [abstract 627]. 19th Conference on Retroviruses and Opportunistic Infections; 5 \u2013 8 March 2012; Seattle USA"},{"key":"e_1_3_1_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60918-1"},{"key":"e_1_3_1_48_1","unstructured":"Ramanathan S Wei X Szwarcberg J Exposure\/Response Analysis of Once-daily Elvitegravir Administered as Elvitegravir\/Cobicistat\/Emtricitabine\/Tenofovir Single-tablet Regimen in HIV-1+ Patients [abstract 622]. 19th Conference on Retroviruses and Opportunistic Infections; 5 \u2013 8 March 2012; Seattle USA"},{"key":"e_1_3_1_49_1","unstructured":"Lepist E Murray B Tong L Effect of Cobicistat and Ritonavir on Proximal Renal Tubular Cell Uptake and Efflux Transporters [abstract A1-1724]. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 17 \u2013 20 September 2011; Chicago USA"},{"key":"e_1_3_1_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32834b4d48"},{"key":"e_1_3_1_51_1","unstructured":"German P Lui C Warren D Effect of cobicistat on glomerular filtration rate (GFR) in subjects with normal and impaired renal function [abstract H2-804]. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 17 \u2013 20 September 2011; Chicago USA"},{"key":"e_1_3_1_52_1","doi-asserted-by":"publisher","DOI":"10.1086\/655681"},{"key":"e_1_3_1_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60918-0"},{"key":"e_1_3_1_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60917-9"},{"key":"e_1_3_1_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61029-0"},{"key":"e_1_3_1_56_1","unstructured":"Antiviral Drugs Advisory Committee Meeting Briefing Document (Gilead Sciences). Elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate single-tablet regimen (EVG\/COBI\/FTC\/TDF Quad STR) for treatment of HIV-1 infection in adults. 2012. Available from: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/AntiviralDrugsAdvisoryCommittee\/UCM303397.pdf [Accessed 11 May 2012]"},{"key":"e_1_3_1_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70249-3"},{"issue":"1","key":"e_1_3_1_58_1","first-page":"S11","article-title":"Resistance and cross-resistance to first generation integrase inhibitors: insights from a Phase II study of elvitegravir (GS-9137)","volume":"12","author":"McColl D","year":"2007","unstructured":"McColl D, Fransen S, Gupta S, Resistance and cross-resistance to first generation integrase inhibitors: insights from a Phase II study of elvitegravir (GS-9137). Antivir Ther 2007;12(Suppl 1):S11","journal-title":"Antivir Ther"},{"issue":"1","key":"e_1_3_1_59_1","first-page":"A137","article-title":"Evolution of resistance to the HIV integrase inhibitor (INI) elvitegravir can involve genotypic switching among primary INI resistance patterns [abstract 16]","volume":"14","author":"Waters J","year":"2009","unstructured":"Waters J, Margot N, Hluhanich RM, Evolution of resistance to the HIV integrase inhibitor (INI) elvitegravir can involve genotypic switching among primary INI resistance patterns [abstract 16]. Antivir Ther 2009;14(Suppl 1):A137","journal-title":"Antivir Ther"},{"key":"e_1_3_1_60_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32834b34de"},{"key":"e_1_3_1_61_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00894-09"},{"key":"e_1_3_1_62_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01534-07"},{"key":"e_1_3_1_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2011.12.008"},{"key":"e_1_3_1_64_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00470-08"},{"key":"e_1_3_1_65_1","unstructured":"Kodama E Shimura K Sakagami I In vitro antiviral activity and resistance profile of a novel HIV integrase inhibitor JTK-303\/GS-9137 [abstract H-254]. 46th Interscience conference on antimicrobial agents and chemotherapy (ICAAC); 27 \u2013 30 September 2006; San Francisco USA"},{"key":"e_1_3_1_66_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00984-08"},{"key":"e_1_3_1_67_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708978"},{"issue":"5","key":"e_1_3_1_68_1","first-page":"138","article-title":"Update of the drug resistance mutations in HIV-1: December 2009","volume":"17","author":"Johnson VA","year":"2009","unstructured":"Johnson VA, Brun-Vezinet F, Clotet B, Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 2009;17(5):138-45","journal-title":"Top HIV Med"},{"key":"e_1_3_1_69_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir025"},{"key":"e_1_3_1_70_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283473599"},{"key":"e_1_3_1_71_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010311"},{"key":"e_1_3_1_72_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06170-11"},{"key":"e_1_3_1_73_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06170-11"},{"key":"e_1_3_1_74_1","unstructured":"Soriano V Cox J Eron J. Dolutegravir (DTG S\/GSK1349572) treatment of subjects with raltegravir (RAL) resistance: viral suppression at week 24 in the VIKING Study [Number PS1\/2]. 13th EACS; 12 \u2013 15 October 2011; Belgrade Serbia"},{"key":"e_1_3_1_75_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2012.661713"},{"key":"e_1_3_1_76_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2010.0370"},{"key":"e_1_3_1_77_1","unstructured":"Kawaguchi I Ishikawa T Ishibashi M Gilead integrase inhibitor: safety and pharmacokinetics of single oral dose of JTK 303\/GS-9137 a novel HIV integrase inhibitor in healthy volunteers [abstract no. 580]. 13th conference on retroviruses and opportunistic infections; 5 \u2013 8 February 2006; Denver USA"},{"key":"e_1_3_1_78_1","unstructured":"Ramanathan S Wright M West S Pharmacokinetics metabolism and excretion of ritonavir-boosted GS-9137 (Elvitegravir) [abstract 30]. 8th International Workshop on Clinical Pharmacology of HIV Therapy; 16 \u2013 18 April 2007; Budapest Hungary"},{"key":"e_1_3_1_79_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181eb376b"},{"key":"e_1_3_1_80_1","unstructured":"Mathias A Koziara J Wei L Effect of acid reducing agents on the relative bioavailability and pharmacokinetics of cobicistat-boosted elvitegravir [abstract P 13]. 12th International Workshop on Clinical Pharmacology of HIV Therapy; 13 \u2013 15 April 2011; Miami USA"},{"key":"e_1_3_1_81_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00341-07"},{"key":"e_1_3_1_82_1","unstructured":"German P Wang M Warren D Kearney BP. Pharmacokinetic interaction between norgestimate\/ethinyl estradiol and EVG\/COBI\/FTC\/TDF single tablet regimen [abstract O_17]. 12th International Workshop on Clinical Pharmacology of HIV Therapy; 13 \u2013 15 April 2011; Miami USA"},{"key":"e_1_3_1_83_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318151fd9a"},{"key":"e_1_3_1_84_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318050d88c"},{"key":"e_1_3_1_85_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318183a982"},{"key":"e_1_3_1_86_1","doi-asserted-by":"publisher","DOI":"10.1177\/135965350801300813"},{"key":"e_1_3_1_87_1","unstructured":"Mathias A West S Enejosa J Kearney B. A pharmacokinetic interaction between lopinavir\/r and elvitegravir [abstract A-1418]. 47th Interscience conference on antimicrobial agents and chemotherapy; 17 \u2013 20 September 2007; Chicago USA"},{"key":"e_1_3_1_88_1","unstructured":"Ramanathan S Mathias A Hinkle J Clinical pharmacokinetics of once-daily elvitegravir boosted by atazanavir versus ritonavir [abstract O18]. 9th International Workshop on Clinical Pharmacology of HIV Therapy; 7 \u2013 9 April 2008; New Orleans USA"},{"key":"e_1_3_1_89_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.168"},{"key":"e_1_3_1_90_1","unstructured":"Ramanathan S Mathias A Shen G Lack of clinically relevant drug-drug interaction between ritonavir-boosted GS-9137 (elvitegravir) and fosamprenavir\/r [abstract WEPEB014]. 4th International conference on HIV pathogenesis treatment and prevention; 22 \u2013 25 July 2007; Sydney Australia"},{"key":"e_1_3_1_91_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181ba4536"},{"key":"e_1_3_1_92_1","unstructured":"Ramanathan S Wang H Custodio J Pharmacokinetics of EVG\/COBI\/FTC\/TDF single tablet regimen following treatment with EFV\/FTC\/TDF (Atripla) in healthy subjects [abstract O_21]. 13th International Workshop on Clinical Pharmacology of HIV Therapy; 16 \u2013 18 April 2012; Barcelona Spain"},{"key":"e_1_3_1_93_1","unstructured":"Ruane P DeJesus E Berger D GS-7340 25 mg and 40 mg demonstrate superior efficacy to tenofovir 300 mg in a 10-day monotherapy study of HIV-1+ patients [abstract 103]. 19th Conference on Retroviruses and Opportunistic Infections; 5 \u2013 8 March 2012; Seattle USA"},{"key":"e_1_3_1_94_1","unstructured":"Ramanathan S Wei X Custodio J Pharmacokinetics of a novel EVG\/COBI\/FTV\/GS-7340 single tablet regimen [abstract O_13]. 13th International Workshop on Clinical Pharmacology of HIV Therapy; 16 \u2013 18 April 2012; Barcelona Spain"},{"key":"e_1_3_1_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)62041-9"},{"key":"e_1_3_1_96_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.370"},{"key":"e_1_3_1_97_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00251-06"},{"key":"e_1_3_1_98_1","first-page":"354908","article-title":"Tenofovir nephrotoxicity: 2011 update","volume":"2011","author":"Fernandez-Fernandez B","year":"2011","unstructured":"Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat 2011;2011:354908. [Epub 2011 Jun 7]","journal-title":"AIDS Res Treat"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/14656566.2012.712514","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:00:37Z","timestamp":1772762437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/14656566.2012.712514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,31]]},"references-count":96,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1517\/14656566.2012.712514"],"URL":"https:\/\/doi.org\/10.1517\/14656566.2012.712514","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,31]]}}}